Monique Adams is the Executive Director, Global Head of Diversity and Inclusion in Clinical Trials, or DICT, at Sanofi where she drives the pharmaceutical company’s vision, strategy, and implementation of a holistic framework for DICT. Monique has a Ph.D. in Pharmacology from the University of Washington and received her M.S. in Physiology from Southern Illinois University.

RDML Richardae Araojo serves as the Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity at the U.S. Food and Drug Administration. In this role she provides leadership, oversight, and direction on minority health, health disparity, and health equity matters for the Agency.

She is currently working with industry sponsors to develop and implement diversity in clinical trials efforts.

Robert E. Fullilove, EdD is the Associate Dean for Community and Minority Affairs, Professor of Clinical Sociomedical Sciences and the co-director of the Cities Research Group. From 1995-2001, he served on the Board of Health Promotion and Disease Prevention at the Institute of Medicine at the National Academy of Sciences. In 1998 he was appointed to the Advisory Committee on HIV and STD Prevention at the Centers for Disease Control. Finally, between 2004-2007, he served on the National Advisory Council for the National Center for Complementary and Alternative Medicine at the National Institutes of Health. Since 2010, he has been teaching public in 6 NY prisons and serves as the Senior Advisor to BPI's public health program.

Dr. Foster is a consultant to the Society for Clinical Research Sites and Vice President of Diversity, Equity, and Inclusion. In her role, she is responsible for building relationships with the industry that help amplify the voice of the clinical research site. She has been integrally involved in that role for SCRS for over six years. Her responsibilities include oversite of the SCRS Diversity Project focused on on-site knowledge, education, and engagement in diversity in clinical trials. Over the past two decades, Diana has addressed audiences across five continents, published multiple papers and articles, and written five authoritative industry books, including “Global Issues in Patient Recruitment and Retention.”

Dr. Jones-Burton is a seasoned pharmaceutical executive, with significant experience leading clinical trial development for multiple medicines. She combines her leadership in research and people development with her clinical acumen in order to positively impact the lives of patients and communities who suffer with chronic diseases. Charlotte earned a medical degree and Master of Science degree in Epidemiology and Preventive Medicine from the University of Maryland School of Medicine. She founded Women of Color in Pharma, a non-profit professional society focused on transforming the pharmaceutical and life sciences landscape with women of color.

Amy Sitnick is Vice President of Marketing at Greenphire, a dynamic fintech company focused on clinical trial financial automation. She is responsible for showcasing the innovation of the company, from the product and IT departments to the client-focused operations teams, to increase brand awareness and create loyalty amongst clinical research stakeholders across the globe. Prior to joining Greenphire in 2018, Amy held Marketing leadership roles within business-to-business financial services companies, including PNC bank, FS Investments and SEI. In addition, she has been a community activist since the age of 18, leading and participating in organizations both in an outside of work that focus on inclusion.

Barbara Bierer, M.D., a hematologist-oncologist, is Professor of Medicine at Harvard Medical School and the Brigham and Women’s Hospital (BWH). Dr. Bierer co-founded and now leads the Multi-Regional Clinical Trials Center of BWH and Harvard (MRCT Center, www.mrctcenter.org), a collaborative effort to improve standards for the planning, conduct, and regulatory environment of international clinical trials. She is the Director of the Regulatory Foundations, Ethics, and the Law at the Harvard Catalyst (https://catalyst.harvard.edu) and Director of Regulatory Policy for SMART IRB (www.SMARTIRB.org). She currently serves on the BODs of Management Sciences for Health, Edward P. Evans Foundation, and Vivli.

Kristine joins Inside Edge with both business and academic experience in qualitative and quantitative research. Formerly with a public policy research company, Kristine had exposure to data collection, data analysis, and decision-makers in the public and private sectors. Her interaction with multiple stakeholders – both professionally and academically – on a day-to-day basis has provided her with the ability to develop strong relationships with partners with quick and efficient interaction and problem-solving skills. At Inside Edge, Kristine’s role focuses on recruitment and retention of diverse clinical trial populations through community engagement. Kristine graduated Cum Laude from Rutgers University

Monica L. Baskin, PhD is a Professor of Preventive Medicine at the University of Alabama at Birmingham (UAB) School of Medicine and Associate Director for Community Outreach and Engagement at the O’Neal Comprehensive Cancer Center at UAB. She received her Bachelor of Arts in psychology and sociology from Emory University, and a Master of Science in community counseling and Ph.D. in counseling psychology from Georgia State University. She is a licensed psychologist whose research focuses on minority health and health disparities. Her research utilizes community-based participatory methods to better understand and address individual, family, and environmental factors associated with the prevention and control of chronic diseases.

Latha Palaniappan MD, MS, is an internist, clinical researcher, and population health scientist. Her research has focused on the study of diverse populations, chronic disease and prevention. Dr. Palaniappan specifically seeks to address the gap in knowledge of health in Asian subgroups and other understudied racial/ethnic minorities (PACS 5R01DK081371, CASPER R01HL126172, and CAUSES R01MD007012). She is currently working on implementation of evidence based genetic and pharmacogenetic testing as the Scientific Director of Precision Genomics and Pharmacogenomics in Primary Care. She is the Faculty co-Director of the Stanford Biobank, designed to accelerate translatable scientific discoveries.

Dr. Vasisht leads the FDA Office of Women’s Health in their work to protect and advance the health of women through scientific programs, policy, research, education, stakeholder collaboration, and outreach that incorporate an understanding of sex and gender differences to facilitate FDA decision making. She also serves as advisor to the Commissioner and key Agency officials on scientific, ethical, and policy issues and represents FDA on cross Agency expert committees focused on the health of women. She is board-certified in internal medicine and adult endocrinology. She completed her internal medicine and fellowship at the University of Chicago Hospitals and obtained her medical degree from the University of Medicine and Dentistry of NJ.

Sunita Dhar is an Executive Medical Group Director in Clinical Safety and the Franchise head for the I2O portfolio at Genentech. Sunita joined the industry after 12 years of clinical practice and has over seventeen years of experience in drug development, safety science, and pharmacovigilance across multiple therapeutic areas. Prior to joining Roche/Genentech in 2011, she led the drug safety department at a mid-size biopharmaceutical company in the Bay Area. Sunita is passionate about making a positive impact on the growth and development of colleagues, bringing transformative therapies to patients, and improving patient access beyond regulatory approval through new innovative tools, technology, and smart data analytics.

Mark McCarthy is Executive Director of Human Genetics at Genentech where he oversees the use of human genetics to support target and biomarker discovery within the company. Prior to his move to industry 2 years ago, Mark was the Robert Turner Professor of Diabetic Medicine at the University of Oxford, UK where his group was focused on understanding the genetic basis of type 2 diabetes and related conditions. Working with a network of collaborators across the globe, Mark's research led to the discovery and functional interpretation of many hundreds of loci influencing type 2 diabetes risk. This work provided fundamental insights into the biology of metabolic disease that have laid the foundation for clinical translation.

Michele Russell-Einhorn, JD is the Chief Compliance Officer and Institutional Official for Advarra, a research compliance company with IRB Services, IBC Services, consulting and technology solutions for clinical research. Her expertise is in the areas of protection of human subjects in research, scientific review of cancer research and research administration generally. Previously, she was the Vice President for Human Research Protections at Schulman IRB and prior to that she served for 11 years as the Senior Director, Office for Human Research Studies at the Dana-Farber Cancer Institute where she was responsible for the management and support of scientific review and institutional review board review, as well as other regulatory matte

Jessica is a Patient Engagement leader who brings to Legacy Health Strategies a combined acumen of medicine and law, together with innovative thinking, to drive the culture change of increasing patient perspectives in medical product development to result in mutually beneficial outcomes for patients and industry. She is known as a credible and trusted thought-leader and collaborator, bringing novel solutions, digital strategies, and patient-centered approaches to biotech, med tech and pharmaceutical industries and across multi-stakeholder groups. She has deep knowledge of the pharmaceutical industry from leadership positions at GlaxoSmithKline and Takeda where she focused on building patient perspectives into the process of R&D.

Dr. Hindorff is a Program Director in the Division of Genomic Medicine at NHGRI and leads programs in genomic medicine and population genomics, including the Clinical Sequencing Evidence-Generating Research (CSER) program, the Population Architecture using Genomics and Epidemiology (PAGE) program, the online NHGRI-EBI GWAS Catalog, and the Polygenic Risk Score (PRS) Diversity Consortium. She has authored or co-authored over 100 publications and enjoys working with trainees and experienced investigators alike. In addition to her scientific portfolio, Dr. Hindorff is broadly interested in health information disparities, the integration of genomic tests into clinical care and practical issues related to large-scale epidemiological studies.

LaShell Robinson has a Master of Science in Biomedical Engineering from the University of South Florida. She is a proud alumna of Tuskegee University where she obtained a Bachelor of Science in both Biology & Physics. Here she saw firsthand the impact historical clinical trial patient experiences had on communities of color perception of research. This continues to fuel and influence her passion for educating others about clinical research and patient engagement. She brings 10 years of clinical trial experience across therapeutic areas including neuroscience, immunology, and cardiovascular. LaShell is currently the Clinical Operations Lead for Diversity & Inclusion in Clinical Trials department.

Dr. Fabian Sandoval, President & CEO, has over 25 years of bench to bedside research experience. His diversified research career has been in academia, healthcare systems and the public sector. He received his Bachelors of Science in molecular and cellular biology from Marymount University, and his Doctorate of Medicine from the Autonomous University of Guadalajara, School of Medicine. Before opening the doors to Emerson Clinical Research Institute (ECRI) Dr. Sandoval’s research activities have included bench research at the National Institutes of Neurological Disorders and Stroke (NINDS) where he focused his work on Early Onset Alzheimer’s Disease, and Cretzfelt-Jakob Disease. At the NIHs’ Clinical Center conducting research in the outpa

Adam is the Founder and Chief Executive Officer at ClinArk. The work at ClinArk is centered around empathy and bringing diverse perspectives together through community engagement with the goal of helping shape better trials. Most importantly, Adam is also a husband to an amazing wife and a dad to three awesome kids.

Born and raised in Mexico, Lorena is a people oriented and sensitive change agent. She is currently leading BMS’s R&D efforts on Diversity in Clinical Trials. After more than 10 years in Commercial roles in the industry, she decided to pursue a career with stronger impact and benefit for patients and underserved populations around the world. As a Latina, Immigrant and a Working Mom, Lorena is now connecting her purpose and power. She holds a BA in International Business and Masters in Strategic Management and Human Capital. She believes in the value of connecting others and is proud of cultivating networks, helping whenever is needed as an active member of WOCIP, the Red Shoe Movement, and her Town's Diversity Committee.

Karri Venn brings over 22 years of clinical research experience working at LMC Manna Research. Ms. Venn has brought experience, knowledge and passion to many of the positions held at LMC Healthcare. Present role is as President, Research with a key responsibility of managing a 20-site integrated clinical research network across multiple therapeutic areas in Canada. Experience in all phases and special expertise in real world/big data, DCT and diversity and inclusion efforts to ensure research is a patient care pathway for all Canadians. Ms. Venn also holds a CEO position with hyperCORE International - a super network of premier research sites across 5 countries including North and South America.

I’ve worked in healthcare for the past 30 years, and Astellas for the last 15 years, in a variety of leadership roles from manufacturing to sales and marketing as well as strategy, change and innovation. The past several years at Astellas have enabled me to discover my real passion is for helping to create a meaningful and lasting impact through the creation and delivery of “even more” VALUE for the patients that we serve. As head of Patient Partnership's, me and my team have the opportunity to create authentic platforms for Astellas colleagues across our business to better understand and address what truly matters most to patients and their families.